Authors:
Rex, JH
Walsh, TJ
Nettleman, M
Anaissie, EJ
Bennett, JE
Bow, EJ
Carillo-Munoz, AJ
Chavanet, P
Cloud, GA
Denning, DW
de Pauw, BE
Edwards, JE
Hiemenz, JW
Kauffman, CA
Lopez-Berestein, G
Martino, P
Sobel, JD
Stevens, DA
Sylvester, R
Tollemar, J
Viscoli, C
Viviani, MA
Wu, T
Citation: Jh. Rex et al., Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses, CLIN INF D, 33(1), 2001, pp. 95-106
Authors:
Boogaerts, M
Winston, DJ
Bow, EJ
Garber, G
Reboli, AC
Schwarer, AP
Novitzky, N
Boehme, A
Chwetzoff, E
De Beule, K
Citation: M. Boogaerts et al., Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy- A randomized, controlled trial, ANN INT MED, 135(6), 2001, pp. 412-422
Authors:
Laverdiere, M
Rotstein, C
Bow, EJ
Roberts, RS
Ioannou, S
Carr, D
Moghaddam, N
Citation: M. Laverdiere et al., Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients, J ANTIMICRO, 46(6), 2000, pp. 1001-1008
Authors:
Rotstein, C
Bow, EJ
Laverdiere, M
Ioannou, S
Carr, D
Moghaddam, N
Citation: C. Rotstein et al., Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy, CLIN INF D, 28(2), 1999, pp. 331-340
Citation: Ej. Bow et al., Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life, J CL ONCOL, 17(4), 1999, pp. 1267-1273